ZLAB (Zai Lab) Piotroski F-Score: 3 (As of Jun. 26, 2026) — Near Median


ZLAB Zai Lab Ltd ZLAB
64 GF Score
Price $18.52
GF Value $30.30
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Zai Lab Piotroski F-Score?

Zai Lab ZLAB +0.76% 64 Piotroski F-Score is 3 as of Jun. 26, 2026, which is at its 10-year median of 3.00. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,342 Biotechnology companies, Zai Lab ranks better than 54.99% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zai Lab has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Zai Lab's Piotroski F-Score or its related term are showing as below:

ZLAB' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 5
Current: 3

During the past 11 years, the highest Piotroski F-Score of Zai Lab was 5. The lowest was 3. And the median was 3.

Zai Lab  (NAS:ZLAB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zai Lab Piotroski F-Score Related Terms


Zai Lab Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Zai Lab's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab Piotroski F-Score Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 4.00 3.00 4.00

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 3.00 4.00 3.00

ZLAB vs TYRA, TRVI, OCUL: Piotroski F-Score Comparison

For the Biotechnology subindustry, Zai Lab's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zai Lab's Piotroski F-Score falls into.


ZLAB
64GF Score
Zai Lab Ltd ZLAB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -40.727 + -35.963 + -50.409 + -51.016 = $-178.1 Mil.
Cash Flow from Operations was -31.024 + -32.044 + -26.022 + -11.912 = $-101.0 Mil.
Revenue was 109.977 + 116.095 + 127.597 + 99.611 = $453.3 Mil.
Gross Profit was 66.757 + 69.212 + 65.266 + 61.276 = $262.5 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1173.33 + 1164.101 + 1158.94 + 1172.384 + 1095.737) / 5 = $1152.8984 Mil.
Total Assets at the begining of this year (Mar25) was $1,173.3 Mil.
Long-Term Debt & Capital Lease Obligation was $12.1 Mil.
Total Current Assets was $944.7 Mil.
Total Current Liabilities was $393.0 Mil.
Net Income was -80.277 + -41.671 + -81.684 + -48.438 = $-252.1 Mil.

Revenue was 100.504 + 102.265 + 109.07 + 106.487 = $418.3 Mil.
Gross Profit was 65.271 + 65.348 + 66.979 + 67.84 = $265.4 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(988.437 + 987.368 + 985.346 + 1185.753 + 1173.33) / 5 = $1064.0468 Mil.
Total Assets at the begining of last year (Mar24) was $988.4 Mil.
Long-Term Debt & Capital Lease Obligation was $12.3 Mil.
Total Current Assets was $1,041.9 Mil.
Total Current Liabilities was $319.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zai Lab's current Net Income (TTM) was -178.1. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zai Lab's current Cash Flow from Operations (TTM) was -101.0. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-178.115/1173.33
=-0.15180299

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-252.07/988.437
=-0.25501878

Zai Lab's return on assets of this year was -0.15180299. Zai Lab's return on assets of last year was -0.25501878. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zai Lab's current Net Income (TTM) was -178.1. Zai Lab's current Cash Flow from Operations (TTM) was -101.0. ==> -101.0 > -178.1 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=12.107/1152.8984
=0.01050136

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=12.319/1064.0468
=0.0115775

Zai Lab's gearing of this year was 0.01050136. Zai Lab's gearing of last year was 0.0115775. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=944.729/392.982
=2.40400069

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1041.868/319.807
=3.25780236

Zai Lab's current ratio of this year was 2.40400069. Zai Lab's current ratio of last year was 3.25780236. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zai Lab's number of shares in issue this year was 110.739. Zai Lab's number of shares in issue last year was 108.083. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=262.511/453.28
=0.57913652

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=265.438/418.326
=0.63452427

Zai Lab's gross margin of this year was 0.57913652. Zai Lab's gross margin of last year was 0.63452427. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=453.28/1173.33
=0.38631928

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=418.326/988.437
=0.42321969

Zai Lab's asset turnover of this year was 0.38631928. Zai Lab's asset turnover of last year was 0.42321969. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zai Lab has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Zai Lab (ZLAB) has a Piotroski F-Score of 3 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zai Lab and its competitors. This is near median its historical median of 3.00. Over the past decade, Zai Lab's Piotroski F-Score has ranged from 3.00 to 5.00. According to the industry distribution chart, Zai Lab ranks #604 out of 1342 companies in the Biotechnology industry, placing it in the top 45%.
Is Zai Lab's Piotroski F-Score too high?
Zai Lab's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Zai Lab's value of 3 is 0% at this industry median. Based on the distribution chart, Zai Lab ranks #604 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Piotroski F-Score compare to TYRA and TRVI?
According to the Biotechnology industry distribution chart, Zai Lab ranks #604 out of 1342 companies for Piotroski F-Score. This puts Zai Lab in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Zai Lab's value of 3 is 0% at this benchmark. Historically, Zai Lab's own Piotroski F-Score has ranged from 3.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Zai Lab has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zai Lab and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.52 — trading 38.9% below its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 0% at the Biotechnology industry median of 3.00. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Piotroski F-Score is 3 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (ZLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of $18.52 is trading 38.9% below its estimated GF Value™ of $30.30. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for ZLAB:

  • Piotroski F-Score: 3 (near median its 10-year median of 3.00)
  • GF Value™: $30.30 vs. price of $18.52 (38.9% below fair value)
  • GF Score™: 64/100 with 8 warning signs
  • Industry Position: 0% at the Biotechnology median (#604 of 1342)

No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zai Lab Business Description

Other Exchanges 09688:Hong Kong1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for ZLAB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.52
Price
$30.30
GF Value